CAMBRIDGE, United Kingdom & DUBLIN--(BUSINESS WIRE)--The University of Cambridge and Elan Corporation plc. (NYSE: ELN) today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. The Cambridge-Elan Centre will provide a highly interdisciplinary environment uniquely positioned for delivering world-leading translational research focused on innovative therapies for Alzheimer’s and Parkinson’s diseases. This ten-year agreement paves the way for a long-term collaboration between Elan and the University of Cambridge.
